| Metric | Value (₹ Cr) | vs Q3 FY26 |
|---|---|---|
| Revenue | 176.89 | 1.7% |
| Total Income | 189.29 | 3.2% |
| Expenditure | 150.19 | 2.9% |
| PBT | 40.20 | 38.0% |
| Net Profit | 29.90 | 35.1% |
| OPM | 19.18% | 1.77pp |
| NPM | 15.80% | 3.74pp |
| EPS | 18.08 | 35.1% |
RPG Life Sciences Q4 FY26 Revenue up 23.6%, Recommends 300% Dividend
29 Apr 2026 · 29 Apr, 8:52 pm
Summary
RPG Life Sciences Limited announced strong financial results for Q4 and FY26, with Q4 revenue growing 23.6% year-on-year to ₹176.9 crores and full-year revenue increasing 8.3% to ₹707.5 crores. The company maintained healthy EBITDA margins of 25.6% in Q4 and 24.4% for FY26, driven by robust performance in its Domestic Formulation business which consistently outperformed market growth. A notable comeback from the API division, registering 144.3% growth in Q4, also contributed significantly. Mr. Ashok Nair, Managing Director, highlighted solid momentum built on operational discipline and focus on key brands, expressing intentions to strengthen the product pipeline and expand global footprint.
Key Highlights
- 1
Revenue from operations in Q4 FY26 increased by 23.6% year-on-year to ₹176.9 crores.
- 2
For the full financial year 2026, revenue from operations grew by 8.3% to ₹707.5 crores.
- 3
The company maintained healthy profitability with an EBITDA margin of 25.6% in Q4 FY26 and 24.4% for the full year FY26.
- 4
The Domestic Formulation (DF) business delivered strong market-beating growth of 18.2% in Q4 FY26 and 13.7% for the full year.
- 5
The API division demonstrated a significant comeback, registering a growth of 144.3% in Q4 FY26 following the restoration of its manufacturing unit.
- 6
The Board of Directors recommended a final dividend of ₹24 per equity share for FY25-26, equivalent to 300% on the face value of ₹8.
Management Comments
Mr. Ashok Nair
Overall, we have built solid momentum with healthy growth in Q4 and for the full fiscal year, driven by sharper field effectiveness, operational discipline and an unwavering focus on our key brands. The resilience demonstrated by our API business during the year reflects the strength of our teams and the robustness of our operations. Looking ahead, we intend to strengthen our new product pipeline, sharpen equity of our existing brands, and drive field force effectiveness. We are also working towards widening our global footprint across fast-growing markets.
Informational and educational content only. Not investment advice.